Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

•Post-hoc analysis of uptake and outcomes of subsequent therapy following afatinib.•High uptake of subsequent therapy (71% of patients) following first-line afatinib.•Provocative overall survival in patients who received sequential afatinib/osimertinib.